AnalystsNaureen QuibriaNaureen Quibria's Stock Forecasts
AnalystsNaureen Quibria
Sectors:
Industries:
Analyst Ranking
Bottom 5%
#4647 out of 4870 analysts
Average Return
-54.37%
Win Rate
7%1 out of 14
Risk vs Reward
Poor
Good
Naureen Quibria's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Fennec Pharmaceuticals IncFENC | +11.95% | $7.11 | $7.96 | 2022-09-07 - 2023-09-06 | Buy |
Naureen Quibria Analyst Color
Get additional color on Naureen Quibria's coverage of popular stocks
Naureen Quibria's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biomea Fusion IncBMEA | 1 | Buy | $25.00 | +1,131.53% | Initiates Coverage On | 8 months ago |
Immutep LtdIMMP | 1 | Buy | $10.00 | +498.80% | Initiates Coverage On | a year ago |
Erasca IncERAS | 1 | Buy | $8.00 | N/A | Initiates Coverage On | a year ago |
Carisma Therapeutics IncCARM | 1 | Buy | $10.00 | N/A | Initiates Coverage On | 2 years ago |
Immunocore Holdings PLCIMCR | 1 | Buy | $84.00 | N/A | Initiates Coverage On | 2 years ago |
Day One Biopharmaceuticals IncDAWN | 1 | Buy | $40.00 | N/A | Initiates Coverage On | 2 years ago |
Fennec Pharmaceuticals IncFENC | 1 | Buy | $11.00 | N/A | Initiates Coverage On | 3 years ago |
Chimerix IncCMRX | 2 | Buy | $7.00 | N/A | Initiates Coverage On | 3 years ago |
Oncternal Therapeutics IncONCT | 1 | Strong Buy | $70.00 | N/A | Initiates Coverage On | 3 years ago |
Genenta Science SpaGNTA | 1 | Strong Buy | $21.00 | N/A | Initiates Coverage On | 3 years ago |
Ayala Pharmaceuticals IncAYLA | 1 | Strong Buy | $22.00 | N/A | Initiates Coverage On | 3 years ago |
Kazia Therapeutics LtdKZIA | 1 | Strong Buy | $900.00 | N/A | Initiates Coverage On | 4 years ago |
Oncorus IncONCR | 1 | Strong Buy | $35.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.